301 OMX-0407, a highly potent SIK3 inhibitor, sensitizes tumor cells to apoptosis and eradicates tumors in combination with PD-1 inhibition

• Christina Hartl,
• Tillmann Michels,
• Ronny Milde,
• Vanessa Klein,
• Philipp Beckhove,
• Hannes Loferer,
• Stefan Bissinger

Affiliations

Christina Hartl

1Dana Farber Cancer Institute, Boston, MA, USA

Tillmann Michels

1iOmx Therapeutics AG, Martinsried/Munich, Germany

Ronny Milde

1iOmx Therapeutics AG, Martinsried/Munich, Germany

Vanessa Klein

1iOmx Therapeutics AG, Martinsried/Munich, Germany

Philipp Beckhove

2RCI Center for Interventional Immunology, Regensburg, Germany

Hannes Loferer

1iOmx Therapeutics AG, Martinsried/Munich, Germany

Stefan Bissinger

1iOmx Therapeutics AG, Martinsried/Munich, Germany